| Marlborough Health & Rehabilitation Center | |
| 85 Stage Harbor Road, Marlborough, Connecticut 06447 | |
| (860) 295-9531 | |
| Name | Marlborough Health & Rehabilitation Center |
|---|---|
| Location | 85 Stage Harbor Road, Marlborough, Connecticut |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 120 |
| Occupancy Rate | 71.58% |
| Medicare ID (CCN) | 075384 |
| Legal Business Name | Marlborough Health Care Center,inc |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1316005242 |
| Organization Name | MARLBOROUGH HEALTH CARE CENTER.,INC |
| Address | 85 Stage Harbor Road, Marlborough, CT 06447 |
| Phone Number | 860-295-9531 |
News Archive
The World Health Organization has today issued new recommendations to tackle tuberculosis, a respiratory disease, in the wake of coronavirus spreading across continents.
The combined use of fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) identified non-small cell lung cancer (NSCLC) patients with rare or novel anaplastic lymphoma kinase (ALK) gene rearrangements, not otherwise identified by FISH alone, that showed response to crizotinib treatment.
A study publishing in the latest issue of Health Services Research is one the few published evaluations of the Centers for Medicare and Medicaid Services Quality Improvement Organizations (QIO).
Liquidia Technologies today announced a collaboration with the PATH Malaria Vaccine Initiative (MVI) to explore the use of the company's PRINT® particle technology to design next generation malaria vaccines. PRINT technology offers unprecedented control of particle size, shape and chemistry in a highly consistent and scalable manufacturing process, and will be used to deliver a protein in combination with immune stimulating molecules.
› Verified 7 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
The World Health Organization has today issued new recommendations to tackle tuberculosis, a respiratory disease, in the wake of coronavirus spreading across continents.
The combined use of fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) identified non-small cell lung cancer (NSCLC) patients with rare or novel anaplastic lymphoma kinase (ALK) gene rearrangements, not otherwise identified by FISH alone, that showed response to crizotinib treatment.
A study publishing in the latest issue of Health Services Research is one the few published evaluations of the Centers for Medicare and Medicaid Services Quality Improvement Organizations (QIO).
Liquidia Technologies today announced a collaboration with the PATH Malaria Vaccine Initiative (MVI) to explore the use of the company's PRINT® particle technology to design next generation malaria vaccines. PRINT technology offers unprecedented control of particle size, shape and chemistry in a highly consistent and scalable manufacturing process, and will be used to deliver a protein in combination with immune stimulating molecules.
› Verified 7 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 1 |
| Total Amount of Fines in Dollars | $6500 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 1 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 16.6 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 10.37 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 48.21 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 0.39 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 4.78 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 5.56 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 3.01 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 96.99 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 19.08 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 70.98 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 0.41 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 34.88 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 29.96 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 7.55 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 100 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 79.96 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 83.29 | 82.93 |
News Archive
The World Health Organization has today issued new recommendations to tackle tuberculosis, a respiratory disease, in the wake of coronavirus spreading across continents.
The combined use of fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) identified non-small cell lung cancer (NSCLC) patients with rare or novel anaplastic lymphoma kinase (ALK) gene rearrangements, not otherwise identified by FISH alone, that showed response to crizotinib treatment.
A study publishing in the latest issue of Health Services Research is one the few published evaluations of the Centers for Medicare and Medicaid Services Quality Improvement Organizations (QIO).
Liquidia Technologies today announced a collaboration with the PATH Malaria Vaccine Initiative (MVI) to explore the use of the company's PRINT® particle technology to design next generation malaria vaccines. PRINT technology offers unprecedented control of particle size, shape and chemistry in a highly consistent and scalable manufacturing process, and will be used to deliver a protein in combination with immune stimulating molecules.
› Verified 7 days ago
Marlborough Health & Rehabilitation Center Location: 85 Stage Harbor Road, Marlborough, Connecticut 06447 Phone: (860) 295-9531 |